Women want Apotex to pay for unwanted pregnancies

Eric Palmer Forty-five women who had turned to Apotex for contraceptives to avoid having children are now looking to the Canadian drugmaker to help them pay for their babies, or their ...

JVs like Pfizer, Hisun hookup provide Chinese companies shot at Western markets

Eric Palmer Joint ventures with Chinese companies have been seen as a way for Big Pharma to get better traction in the exploding China market. But it is not a one-way street. Chinese ...

FDA: Merck’s sleep drug suvorexant effective, but safety issues draw heavy flak

John Carroll FDA staffers found clear evidence to prove that Merck's blockbuster drug candidate suvorexant is quite effective in promoting sleep, but the internal review cites multiple ...

Actavis nabs Warner Chilcott in a $8.5B stock swap

Tracy Staton Actavis and Warner Chilcott have struck a deal. And it's bigger than the $ 5 billion-or-so that was bandied about while the companies negotiated. About $ 3 billion ...

XenoPort shares skid after MS drug proves to be a lemon in PhIII

John Carroll Shares of XenoPort skidded lower this morning after the biotech announced its lead experimental drug had decisively failed a late-stage study for spasticity triggered by ...

Elan orchestrates $693M biotech buyout, $90M spinout in deal frenzy

John Carroll In a dealmaking frenzy, cash-rich Elan has agreed to pay up to $ 693 million for a biotech company focused on rare diseases, picked up a big share of a start-up specialty ...

Evotec, Harvard partner up to develop new antibacterials

Emily Mullin More biotech companies are forging academic partnerships as they downsize their internal R&D efforts, and another outfit to ride that wave is Germany's Evotec AG. ...

Novo Nordisk completes PhIII hemophilia trial with positive results

Emily Mullin In a Friday announcement, Novo Nordisk said it completed the first phase III trial of its drug N9-GP for hemophilia B patients. FierceBiotech News

Mined doctor-patient data gives drugmakers insight for targeted marketing

Carly Helfand The recent layoffs of hundreds of drug sales reps mean there are fewer people in the field calling on doctors to see what they are prescribing. But they don't have ...

Third Rock Ventures adds biotech veterans to team

Alok Saboo FierceBiotech News

Australian judge kills Merck Vioxx class action settlement

Eric Palmer A federal judge in Australia has put the kibosh on a half-million-dollar settlement over ill effects of Merck's ($ MRK) painkiller Vioxx, a drug that has spawned ...

AbbVie, Galapagos extend JAK1 pact into Crohn’s disease with $50M carrot

Ryan McBride The North Chicago, IL-based drug giant and Belgium's Galapagos have agreed to expand their collaboration on an oral JAK1 inhibitor to include Crohn's disease. FierceBiotech ...
Page 20 of 34« First...10...1819202122...30...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS